Видео ютуба по тегу Dr. Arnon Kater

Subcutaneous Epcoritamab for Richter's Syndrome - Dr. Arnon Kater ASH 2022
Subcutaneous Epcoritamab for Richter's Syndrome - Dr. Arnon Kater ASH 2022
Immune Changes After Treatment with Venetoclax + Rituximab in CLL - Dr. Arnon Kater ASH 2022
Immune Changes After Treatment with Venetoclax + Rituximab in CLL - Dr. Arnon Kater ASH 2022
Solid Results for Epcoritimab for Relapsed / Refractory CLL - Dr. Arnon Kater
Solid Results for Epcoritimab for Relapsed / Refractory CLL - Dr. Arnon Kater
Use of Bispecific Antibodies in Chronic Lymphocytic Leukemia (CLL) - Dr. Arnon Kater ASH 2021
Use of Bispecific Antibodies in Chronic Lymphocytic Leukemia (CLL) - Dr. Arnon Kater ASH 2021
CLL Horizons 2016: Clinical Trial Uptake and Availability. Dr Arnon Kater
CLL Horizons 2016: Clinical Trial Uptake and Availability. Dr Arnon Kater
CLL Horizons 2016: Watch & Wait. Dr. Arnon Kater
CLL Horizons 2016: Watch & Wait. Dr. Arnon Kater
Hematology & CLL: Research and its Challenges - Arnon P. Kater, MD, PhD and Rosario Custidiano, MD
Hematology & CLL: Research and its Challenges - Arnon P. Kater, MD, PhD and Rosario Custidiano, MD
Managing CLL as a chronic disease in the long term to improve overall outcome
Managing CLL as a chronic disease in the long term to improve overall outcome
How CLL Impacts the Immune System
How CLL Impacts the Immune System
Arnon P Kater, EHA 2018 – TP53 mutations in relapsed/refractory CLL – the MURANO trial
Arnon P Kater, EHA 2018 – TP53 mutations in relapsed/refractory CLL – the MURANO trial
Overcoming mental health issues for patients with CLL
Overcoming mental health issues for patients with CLL
Prof. Kater's highlights from iwCLL 2019 - 3D modeling and the microenvironment
Prof. Kater's highlights from iwCLL 2019 - 3D modeling and the microenvironment
An introduction to the HOVON-141 trial in patients with CLL
An introduction to the HOVON-141 trial in patients with CLL
CLL 19-10-2013 dr.A.Kater
CLL 19-10-2013 dr.A.Kater
Genomic testing can help identify patient risk factors and guide clinical decision-making
Genomic testing can help identify patient risk factors and guide clinical decision-making
An insight into time-limited therapy in CLL
An insight into time-limited therapy in CLL
Pursuing a career in CLL research
Pursuing a career in CLL research
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of C...
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of C...
Taking MRD from trials to the clinic
Taking MRD from trials to the clinic